Britain must do far more to support its entrepreneurs if it wants to produce the next generation of world-leading companies, according to Sir Richard Branson. Writing in a national publication, Branson said
More
President Donald Trump signed an executive order on August 10, 2026, titled “Delivering Gold Standard Childhood Vaccine Recommendations for Americans,” narrowing the recommended childhood vaccine list. The order reduces the number of
More
The prolonged Strait of Hormuz standoff is deepening concerns across pharmaceutical supply chains, with no resolution appearing imminent from either side. President Trump has signalled the US is prepared to let economic
More
The U.S. Environmental Protection Agency has extended its Emerging Viral Pathogen Guidance for Antimicrobial Pesticides in response to the mpox virus, formerly known as monkeypox. The EPA originally developed its Emerging Viral
More
Minnesota has set September 15, 2026, as the deadline for manufacturers to submit reports on products containing intentionally added PFAS that are sold in the state. The reporting requirement applies to any
More
The legal industry is watching closely as big law firms edge toward private equity funding, raising questions about what that model truly means for the profession. The so-called management services structure, the
More
Rolls-Royce and SpaceX are two of the most closely watched stocks in global markets right now, though for very different reasons. Rolls-Royce shares have delivered a staggering 1,276% return over the past
More
The FTSE 250 index has long been a hunting ground for acquirers seeking undervalued British businesses with strong fundamentals and growth potential. Merger and acquisition activity across UK mid-cap stocks has picked
More
Nottingham Forest owner Evangelos Marinakis is suing Crystal Palace in the High Court over a banner displayed by the south London club’s supporters. Lawyers for Marinakis lodged the defamation claim almost a
More
Tenax Therapeutics (Nasdaq: TENX) has announced that its Phase 3 LEVEL clinical trial evaluating TNX-103, an oral form of levosimendan, failed to meet its primary endpoint. The trial, which enrolled 241 patients
More